AX-2025-020979

PT-141 (Bremelanotide) · 10 mg declared · WuXi TIDES (WuXi AppTec Testing Division) · lot WXT-2507-R4042

PASSPURITY ONLY

Report ID: AX-2025-020979
Compound: PT-141 (Bremelanotide)
Compound class: Melanocortin-receptor peptides
Supplier: WXT — WuXi TIDES (WuXi AppTec Testing Division)
Batch / lot: WXT-2507-R4042
Declared label claim: 10mg
Laboratory: Janoshik Analytical
Assay date: 31 Jul 2025
Submitted: 14 Aug 2025
Quarter: 2025-Q3
Submitter: b.kaufmann
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.11	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.89	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — linear precursor (+18 Da)	0.42	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	88.87	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	88.08	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	10.58	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.319	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	93.2	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.85	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.39	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.89	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear with a single visible fibre	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.17	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	9.59	min	9.52 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.15	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	58,829	—	≥ 20,000	PASS
Resolution to nearest impurity	vs melanotan II (C-terminal amide, −1 Da)	1.97	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 58,829, and skew follows the reported asymmetry factor of 1.15. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.42 % impurity against a 99.11 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	PT-141 (Bremelanotide) — main peak	9.59	4,817,053	99.11	—
2	linear precursor (+18 Da)	8.89	20,413	0.42	+18.011
3	melanotan II (C-terminal amide, −1 Da)	9.91	12,151	0.25	-0.984
4	des-acetyl (−42 Da)	9.13	5,832	0.12	-42.011
5	oxidised Trp (+16 Da)	9.25	4,860	0.10	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.85
Counter-ion (acetate)	ion chromatography	5.39
Residual solvent + inorganic residue	estimated	0.89
Total peptide content	by difference	88.87
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.05	99.11	divergence +0.01 pp vs batch median
Total impurities (% area)	0.95	0.89
Largest single impurity (% area)	0.58	0.42
Water (%)	3.9	4.85
Counter-ion (%)	not stated	5.39
Peptide content (%w/w)	91.3	88.87
Endotoxin (EU/mg)	0.75	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 20 d) → laboratory (courier, dry ice, 7 d) → assay.
Assay date: 31 Jul 2025
Submitted to the index: 14 Aug 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 1

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

label_claim14 Aug 2025

A retail vial is also a test of the label. Declared claim 10 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.

Section 7

Related records

Same batch — lot WXT-2507-R4042 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020972	WXT-2507-R4042	PeptideMeter	2025-Q3	99.04	5.29	—	Buyer-sourced	1	MARGINAL
AX-2025-020973	WXT-2507-R4042	Kestrel	2025-Q3	99.75	4.62	—	Buyer-sourced	0	PASS
AX-2025-020974	WXT-2507-R4042	VendorInvestigate	2025-Q3	99.38	4.71	—	Buyer-sourced	0	PASS
AX-2025-020975	WXT-2507-R4042	Janoshik	2025-Q3	98.88	4.76	—	Buyer-sourced	0	PASS
AX-2025-020976	WXT-2507-R4042	Medutest	2025-Q3	99.00	4.50	101.5	Buyer-sourced	0	PASS
AX-2025-020977	WXT-2507-R4042	PeptideMeter	2025-Q3	98.98	4.65	94.0	Buyer-sourced	0	PASS
AX-2025-020978	WXT-2507-R4042	Medutest	2025-Q3	98.65	4.38	—	Buyer-sourced	0	PASS
AX-2025-020980	WXT-2507-R4042	PeptideMeter	2025-Q3	99.26	4.60	95.9	Buyer-sourced	0	PASS
AX-2025-020981	WXT-2507-R4042	Nordanalyt	2025-Q3	99.03	4.87	105.2	Buyer-sourced	0	PASS
AX-2025-020982	WXT-2507-R4042	Janoshik	2025-Q3	99.32	4.57	99.4	Buyer-sourced	1	MARGINAL
AX-2025-020983	WXT-2507-R4042	Janoshik	2025-Q3	98.97	5.11	—	Laboratory-retained	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

All PT-141 (Bremelanotide) records n=152
All WXT records n=301
All Janoshik records n=2989
All 2025-Q3 records n=816
PT-141 (Bremelanotide) by supplier
PT-141 (Bremelanotide) impurity profile

Other recent PT-141 (Bremelanotide) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041471	QYB	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	0	PASS
AX-2026-041473	QYB	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	0	PASS
AX-2026-041472	QYB	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041474	QYB	QYB-2607-L4875	VendorInvestigate	2026-Q3	99.16	3.78	95.6	Buyer-sourced	0	PASS
AX-2026-041470	QYB	QYB-2607-L4875	Janoshik	2026-Q3	99.77	4.10	—	Buyer-sourced	0	PASS
AX-2026-042139	JEEP	JEEP-2601-K8195	VendorInvestigate	2026-Q2	98.32	4.29	99.4	Buyer-sourced	1	FAIL
AX-2026-041964	AMB	AMB-2601-M5602	Janoshik	2026-Q2	99.93	3.20	—	Buyer-sourced	0	PASS
AX-2026-041664	FGP	FGP-2602-Y8741	Janoshik	2026-Q2	99.90	4.48	106.5	Buyer-sourced	0	PASS

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043376	Semaglutide	WXT-2604-C3248	Janoshik	2026-Q3	97.08	4.22	—	Buyer-sourced	1	MARGINAL
AX-2026-043429	L-Glutathione (reduced)	WXT-2605-B3833	Nordanalyt	2026-Q3	98.48	6.58	96.9	Supplier-supplied	1	FAIL
AX-2026-043347	Leuprolide	WXT-2604-K2596	PeptideMeter	2026-Q3	99.16	5.99	93.6	Buyer-sourced	0	PASS
AX-2026-043353	Leuprolide	WXT-2604-K2596	Janoshik	2026-Q3	99.19	4.90	95.3	Laboratory-retained	0	PASS
AX-2026-043345	Leuprolide	WXT-2604-K2596	Janoshik	2026-Q3	98.93	5.28	—	Buyer-sourced	0	PASS
AX-2026-043424	L-Glutathione (reduced)	WXT-2605-B3833	PeptideMeter	2026-Q3	98.37	6.86	—	Buyer-sourced	0	FAIL
AX-2026-043374	Semaglutide	WXT-2604-C3248	Janoshik	2026-Q3	97.00	3.56	—	Buyer-sourced	1	MARGINAL
AX-2026-043377	Semaglutide	WXT-2604-C3248	PeptideMeter	2026-Q3	97.20	4.08	—	Buyer-sourced	1	MARGINAL